Industry

  MENLO PARK, Calif.–(BUSINESS WIRE)–Please replace the release with the following corrected version. A multimedia asset accompanying this release and paragraph seven have been removed. The updated release reads: GRAIL ANNOUNCES FINAL RESULTS FROM THE PATHFINDER MULTI-CANCER EARLY DETECTION SCREENING STUDY AT ESMO CONGRESS 2022 Adding Multi-Cancer Early Detection (MCED) Screening to Standard of Care … [Read more…]

In a new L.A. Times ad (Sunday, September 11), AHF’s Housing Is A Human Right highlights results of its recent investigation and tally revealing 4,612 hotel rooms throughout Los Angeles that could be repurposed as housing for homeless and extremely-low-income individuals An average of 1,500 unsheltered or homeless individuals die on the streets of Los … [Read more…]

Adding Multi-Cancer Early Detection (MCED) Screening to Standard of Care Screening More Than Doubled the Number of Cancers Detected 71% of Participants With MCED-Detected Cancers Had Cancer Types With No Routine Screening Tests Available Approximately Half of the MCED-Detected New Cancers Were Stage I or II MCED-Predicted Cancer Signal Origin Had 97.1% Accuracy and Enabled … [Read more…]

Subgroup analysis from the Phase 3 ATHENA trial evaluating Rubraca monotherapy versus placebo (ATHENA-MONO) presented in a Mini Oral session at the ESMO Congress 2022 Results reinforce potential of Rubraca as a first-line maintenance treatment option in a broad population of patients with ovarian cancer irrespective of molecular characteristics, with or without high risk factors … [Read more…]

DESTINY-Lung02 Phase II trial shows clinically meaningful efficacy and favorable safety at 5.4mg/kg vs. 6.4mg/kg dose of AstraZeneca and Daiichi Sankyo’s ENHERTU in HER2-mutant disease Updated results from DESTINY-Lung01 Phase II trial demonstrate continued durable activity across patient subtypes WILMINGTON, Del.–(BUSINESS WIRE)–Detailed positive results from an interim analysis of the DESTINY-Lung02 Phase II trial showed … [Read more…]

Exploratory analysis from POSEIDON Phase III trial also showed trends for overall survival benefit with a limited course of tremelimumab added to IMFINZI and chemotherapy in subgroups with high unmet need WILMINGTON, Del.–(BUSINESS WIRE)–Updated results after approximately four years of follow-up of the POSEIDON Phase III trial showed a limited course of tremelimumab when added … [Read more…]

Nearly three in four patients treated with adjuvant TAGRISSO were alive and disease-free at four years Exploratory results showed TAGRISSO also reduced the risk of disease recurrence in the brain or spinal cord by 76% in patients with Stage II-IIIA disease WILMINGTON, Del.–(BUSINESS WIRE)–Updated results from the pivotal ADAURA Phase III trial showed that AstraZeneca’s … [Read more…]

NESS ZIONA, Israel–(BUSINESS WIRE)–BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer of BiomX, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022.   H.C … [Read more…]

– Updated Results for Vimseltinib Showed Objective Response Rate of 69% in Phase 1, 53% in Phase 2 Cohort A, and 46% in Phase 2 Cohort B; Demonstrated a Clinical Benefit Rate of 100% Across All Phase 1/2 Patients – – Preliminary Patient-Reported Outcome Data in Phase 2 Demonstrate Clinically Meaningful Improvements in Pain and … [Read more…]

Patient-Reported Outcomes with Mirvetuximab Versus Chemotherapy in FORWARD I Study Reinforces Differentiated Tolerability Profile WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced findings from an analysis of patient-reported outcomes (PROs) with mirvetuximab soravtansine (mirvetuximab) versus chemotherapy in the randomized Phase … [Read more…]